# AST-120 (Kremezin®) for the Renal Protection and Attenuation of Decline in Acute Kidney Disease

> **NCT07182422** · PHASE4 · RECRUITING · sponsor: **Chang Gung Memorial Hospital** · enrollment: 100 (estimated)

## Conditions studied

- Acute Kidney Disease
- Acute Kidney Injury (AKI)

## Interventions

- **DRUG:** AST-120 (Kremezin®)

## Key facts

- **NCT ID:** NCT07182422
- **Lead sponsor:** Chang Gung Memorial Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-09-15
- **Primary completion:** 2027-02-11
- **Final completion:** 2027-03-13
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2025-09-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07182422

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07182422, "AST-120 (Kremezin®) for the Renal Protection and Attenuation of Decline in Acute Kidney Disease". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07182422. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*